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Dihydro-leukotriene B4 (a S,12-dihydroxy-eicosatrienoic acid) has been shown to be the primary metabolite of leukotriene 
B, (LTB,) in a variety of cells other than human polymorphonuclear leukocytes (PMNLs). In this report we show that 
dihydro-LTB, is significantly less active than LTB, in different biological assay systems, i.e. leukocyte chemotaxis, che- 
mokinesis, aggregation, adhesion to endothelium and superoxide anion production. This suggests that primary reduction 
constitutes a second so far unknown deactivation pathway for LTB,. 
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1. INTRODUCTION 
Leukotriene Bq serves as an important en- 
dogenous mediator of inflammatory and immune 
reactions [ 1,2]. Its biological effects particularly 
concern responses of phagocytic leukocytes, such 
as chemotactic and chemokinetic movement, ag- 
gregation, adhesion to endothelial cells, increases 
in intracellular calcium levels, enzyme release by 
lysosomal degranulation, production of superox- 
ide anion and hydrogen peroxide and actin 
polymerization [3-51. It has been proposed that 
high- and low-affinity receptors are involved in 
most of these effects [6]. The LTB4 receptor- 
mediated signal transduction is sensitive to per- 
tussis toxin, thus indicating the existence of a 
guanine nucleotide regulatory protein controlling 
Correspondence address: V. Kaever, Abt. Molekularphar- 
makologie, Medizinische Hochschule Hannover, Konstanty- 
Gutschow-Str. 8, D-3000 Hannover 61, FRG 
Abbreviations: LT&, leukotriene Bq; dihydro-LTB4, 
dihydroleukotriene Bd; PMNL, polymorphonuclear leukocyte; 
rp-HPLC, reverse-phase high-performance liquid chroma- 
tography 
the LTB4-induced cleavage of phosphatidylinositol 
4,Sbisphosphate by phospholipase C [7-91 and 
subsequent translocation and activation of protein 
kinase C [lo]. Little is known about the precise 
mechanisms of LTB4 inactivation in vivo. We [ 1 l] 
and others [ 121 have previously reported that LTB4 
can be primarily transformed by reduction of a 
double-bond into a 5,12-dihydroxy-eicosatrienoic 
acid, termed dihydro-LTB4, in different murine 
cells, including mesangial cells, fibroblasts and 
PMNLs, respectively. This represents an alter- 
native metabolic pathway for LTB4 in addition to 
the known w-oxidation by human PMNLs, leading 
to 20-hydroxy/20-carboxy-LTB4 (20-OH/20- 
COOH-LTB4) [ 131. In order to investigate whether 
the formation of dihydro-LTB4 represents an ef- 
fective deactivation step in LTB4 metabolism, we 
compared the biological effects of LTB4 and 
dihydro-LTB4 in human leukocytes. 
2. EXPERIMENTAL 
2.1. Preparation of dihydro-LTB, 
Dihydro-LTB4 was obtained through conversion of LTB4 
(kindly provided by Hoechst AC) by rat mesangial cells. For 
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this purpose 1Opg LTB4 together with trace amounts of 
[-‘H]LTBd (Amersham) were added to 5 x lo6 cells for 4 h under 
serum-free conditions. LTB4 and its metabolites were purified 
by rp-HPLC and solid-phase extraction [ll]. 
2.2. Cells 
Human non-fractionated leukocytes were isolated from 
venous blood (mixed with 3 mmol/l Naz-EDTA as an- 
ticoagulant) of healthy donors by dextran sedimentation [14]. 
The cells were finally suspended in phosphate buffered saline 
(1 x lo6 cells/ml, superoxide anion production) or in complete 
Gey’s solution (always containing 0.5% human serum albumin, 
grade ‘purest’, Behrinwerke) to final concentrations of 1 x lo6 
or 6 x lo6 cells/ml (chemotaxis and adhesion assay, respective- 
ly) or in Ca/Mg-free medium to 10’ cells/ml (aggregation 
assay). For determination of chemokinetic migration PMNLs 
were isolated by centrifugation of the blood in a discontinuous 
gradient of Percoll (Pharmacia) as in [15] and suspended in 
complete Gey’s solution to a concentration of 5 x lo5 cells/ml. 
2.3. Bioassays 
2.3.1. Chemotaxis 
Chemotactic migration towards concentration gradients of 
LTBl and dihydro-LTB4 was assayed in slightly modified 
Boyden chambers with cellulose nitrate filters of 3.0 pm pore 
size (Sartorius) and quantified by the ‘leading front method’ as 
described in [14] with CSa-desarg (peptide derived from comple- 
ment factor 5) as standard. 
2.3.2. Chemokinesis 
These experiments were performed in Sykes-Moore chambers 
at 37°C for 15 min with evenly distributed stimuli to induce un- 
directed, chemokinetic migration [16]. 
2.3.3. Adhesion to guinea-pig aorta 
Adhesion of PMNLs to endothelium of aortic strips was 
measured in a superfusion model [17]. Finally, the numbers of 
adhering PMNLs were counted under the microscope. 
2.3.4. Aggregation 
Assays of this cell function were performed in an ag- 
gregometer as detailed in [ 141. In addition to the experimental 
procedure described there, 2 pg/ml cytochalasin B (Sigma) were 
applied to the samples of leukocyte suspension 3 min before 
Ca/Mg in order to enhance the aggregation response. 
2.3.5. Superoxide anion production 
This was estimated by measuring the change in fer- 
ricytochrome c reduction (Sigma, type III) at 550 nm [18] after 
30 min. 
3. RESULTS AND DISCUSSION 
Several bioassays were carried out to evaluate 
the biological properties of the primary LTB4 
metabolite dihydro-LTB4. Chemotaxis represents 
the most specific biological response of PMNLs to 
LTB4, which displays a half-maximal effect at a 
concentration in the nanomolar range. Fig. 1 shows 
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Fig.1. Effect of LTB4 or dihydro-LTB4 on human leukocyte 
chemotaxis. (A) LTB4 (open bars) or dihydro-LTB., (closed 
bars) were used in the indicated concentrations. Results are the 
mean + SD of 3 experiments with different cells, each 
comprising 5 determinations of the maximal distance of 
migration &m). A Student’s t-test was used to assess the 
significance of the chemotactic properties with * indicating p < 
0.05. Control, spontaneous migration in the absence of a 
stimulus; standard, CSa-desarg (1 tg/ml). (B) The mean values 
shown in A were transformed by subtracting the corresponding 
control values and related to the maximal LTB4 response. LTB4 
(o), dihydro-LTB4 (m). 
that dihydro-LTB4 exhibited a markedly lower 
chemotactic activity than LTB4. The concentration 
of dihydro-LTB4 required for half-maximal 
stimulation of PMNL chemotaxis was about 
lo-20-fold higher than that of LTB4 (fig.lB). In 
comparison with LTB4 a diminished biological ac- 
tivity of dihydro-LTB4 was also observed in the 
stimulation of PMNL chemokinesis, adhesion to 
endothelial cells and aggregation (table 1). In all 
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Table 1 
Effects of LTB4 and dihydro-LTB4 on human leukocyte 
functions 
Control LTB4 Dihydro- C5,- 
LTB4 desarg 
Chemokinesis 
migration index 0 0.73 0.35 2.07 
% LTBd 
response (100) (47.9) (284) 
Aggregation 
A transmission 0 8.7 3.2 nd 
% LTB4 
response (100) (36.8) 
Adhesion 
cells/IO fields 30 58 42 nd 
% LTB4 
response (100) (42.9) 
The effects of LTB4, dihydro-LTB4 and CSa-desarg (lo-’ mol/l 
each) on PMNL chemokinetic movement and on leukocyte 
aggregation and adhesion to endothelial cells, respectively, were 
determined as described in section 2. Results are means from 
duplicate determinations. nd, not determined 
these instances LTB4 was less than half as active as 
LTB4 at a concentration of lo-’ mol/l of both 
substances. The effectiveness of LTB4 to stimulate 
PMNL chemokinesis was low compared to CS,- 
desarg as standard, which was not the case with 
respect to the induction of PMNL chemotaxis 
(fig.1). It has been reported that LTB4 can induce 
the oxidative metabolism of PMNLs [3]. This was 
confirmed in our experiments regarding the reduc- 
tion of cytochrome c by superoxide anion after the 
addition of LTB4 to leukocytes (fig.2). Again 
dihydro-LTB4 was much less active. Even at a con- 
centration of 10e6 mol/l no maximal response was 
achieved by both substances. This questions the in 
vivo relevance of these effects. Deoxyglucose up- 
take by leukocytes or macrophages could not be 
stimulated by LTB4 or its metabolite (not shown). 
Taken together, our results demonstrate that the 
conversion of LTB4 into dihydro-LTB4 causes a 
significant loss of biological activities of LTB4. In 
the chemotaxis assay, which is the most specific 
biological test system for LTB4, dihydro-LTB4 ex- 
hibited less than 10% of the LTB4 activity. Its ef- 
fects on other PMNL functions were also lower 
than those of LTB4 but could not be exactly quan- 
tified as for example superoxide anion production 
did not reach a maximum even at unphysiological 
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Fig.2. Effect of LTBd or dihydro-LTB4 on human leukocyte 
oxidative burst. Superoxide anion production was measured as 
described in section 2. Values are the mean * SD from triplicate 
determinations. LTBI ( q ), dihydro-LTBa (B). 
concentrations (10m6 mol/l). Up to now two major 
routes for LTB4 metabolism have been described. 
In human PMNLs 20-OH-LTB4, which in some 
systems is as potent as LTB4 itself [5], and 
20-COOH-LTB4 are formed [13], but the further 
degradation has to be carried out by other cells. In 
various murine cell types, including neutrophils 
t121, dihydro-LTB4 is the primary LTB4 
metabolite, which can be converted to secondary 
hydrophilic products by these cells [ll]. Our 
studies demonstrate that the primary reduction to 
dihydro-LTB4 is an important alternative route of 
biological inactivation of LTB4. 
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